SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor ...

Cabinet Secretary for Lands, Public Works, Housing, and Urban Development, Alice Wahome, has reaffirmed the Ministry’s ...

Wedbush analyst David Nierengarten maintained a Buy rating on AnaptysBio (ANAB – Research Report) today and set a price target of $40.00. The company’s shares closed yesterday at $16.08.

At close: February 7 at 4:00:00 p.m. EST ...